Insight Molecular Diagnostics Inc. Interest Expense
Insight Molecular Diagnostics Inc. (IMDX) reported Interest Expense of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2017-02-27
- Insight Molecular Diagnostics Inc. interest expense for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Insight Molecular Diagnostics Inc. interest expense for fiscal 2015 was $18.00K.
- Insight Molecular Diagnostics Inc. interest expense for fiscal 2014 was $0.00.
| Period end | Interest Expense 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2015-12-31 | $18.00K 10-K · filed 2017-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |